



Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

October 23, 2023 12:30 PM EDT

FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- [Apollomics Inc.](#) (Nasdaq: [APLM](#)) (the "Company"), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress (ESMO) 2023, being held in Madrid, Spain from October 20-24, 2023.

"The clinical results demonstrate the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations, particularly in Non-Small Cell Lung Cancer (NSCLC) with MetEx14 skipping mutation," said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics. "We are also pleased to see that vebreltinib is making progress in clinical programs for patients with various MET alterations."

In the Phase 2 KUNPENG clinical trial conducted by Apollomics' China partner, Avistone Biotechnology Ltd. (Beijing Pearl Biotechnology Ltd.), vebreltinib showed efficacy in patients with locally advanced or metastatic NSCLC harboring Exon-14 skipping mutations, with an ORR of 75%. Among other notable findings in the KUNPENG study, ORR and disease control rate (DCR) were 100% in patients with brain metastases (n=5) and ORR was 66.7% in patients with liver metastases (n=6).

Preliminary efficacy and safety data from the Phase 2 KUNPENG clinical trial (NCT04258033) is presented in poster 1378P. The poster or abstract are available on the Apollomics website: <https://ir.apollomicsinc.com/news-events/presentations>.

The data from NSCLC patients with MetEx14 skipping mutation showed the following efficacy results:

- Of the 52 patients, 39 achieved complete or partial response, an ORR of 75% (95% CI, 61.1-86.0), median duration of response (DOR) of 15.9 months (95% CI, 9.2-17.8), a high disease control rate (DCR) of 96.2% (95% CI, 86.8 to 99.5). and a notably rapid onset of response with a median time to response of 1 month (95% CI, 1, 2.8).
- In the 35 treatment-naïve patients, ORR was 77.1% (95% CI, 59.9-89.6), with median DOR of 16.5 months (95% CI, 9.2-NE).
- In the 17 patients who received prior systemic treatment, ORR was 70.6% (95% CI, 44.0-89.7), with median DOR of 15.3 months (95% CI, 3.7-17.8).

About vebreltinib (APL-101)

Vebreltinib is a potent, small molecule, orally bioavailable and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. Vebreltinib is under clinical development for treatment of solid tumors with Met alterations by Apollomics globally and by Avistone Biotechnology in China. Vebreltinib NDA for exon-14 skipping NSCLC is under review by NMPA in China.

About [Apollomics Inc.](#)

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics currently has a pipeline of nine drug candidates across multiple programs, six of which are currently in the clinical stage of development. Apollomics' lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes statements that constitute "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of present or historical fact included in this press release, regarding clinical trials and results, as well as the Company's strategy, business plans and objectives of management are forward-looking statements. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics' intellectual property; (v) breaches in data security; and other risks included in the Annual Report on Form 20-F filed with the SEC and other SEC filings that are available publicly on the SEC's website at www.sec.gov. Apollomics undertakes no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws.

CONTACTS

Investor Relations

Peter Vozzo
ICR Westwicke
Peter.Vozzo@westwicke.com

+1-443-213-0505

Media Relations

Sean Leous

ICR Westwicke

Sean.Leous@westwicke.com

+1-646-866-4012